secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2025-01-08T23:59:59+00:00
Accession:  0001104659-25-001869
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel cuts CEO/CFO/CSO 2025 cash comp, grants stock options at $0.4713
------------------------------------------------------------------------

- CEO Vimal Mehta's 2025 cash compensation reduced to $706,558; granted options for 660,000 shares at $0.4713.
- CFO Richard Steinhart's cash comp reduced to $289,800; granted options for 270,000 shares.
- CSO Frank Yocca's cash comp reduced to $290,500; granted options for 270,000 shares.
- Options vest in 12 equal monthly installments; full acceleration on termination without cause or change in control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925001869/0001104659-25-001869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925001869/tm252221d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-001869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer